Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...
An analysis of British records for December 2020-May 2022 is said to show that young women aged 12-29 who received at least one dose of AstraZeneca’s Covid vaccine may...
As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their...
Safety findings in Phase 2 clinical trials have forced Aristea Therapeutics to stop developing its lead candidate RIST4721 for treating serious immune-mediated...
Amgen’s proposed acquisition of Horizon Therapeutics for $28.7 billion, including debt, would be the largest healthcare deal since AstraZeneca’s $39 billion purchase of...
AstraZeneca has entered into an agreement to buy CinCor Pharma, a US-based clinical-stage biopharma focused on developing novel treatments for resistant and uncontrolled...
Two weeks after annnouncing that it would no longer seek to market its Covid-19 vaccine in the US, Anglo-Swedish drugmaker AstraZeneca has unveiled plans to sell its...
The UK’s Center for Process Innovation (CPI) opened its Medicines Manufacturing Innovation Center in Glasgow on Nov. 30, with the aim of accelerating new technologies in...
